You are here: Home » Companies » News
Business Standard

Natco Pharma's API facility near Hyderabad gets 6 USFDA observations

The company said that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust

USFDA | Natco Pharma | Pharma industry

Press Trust of India  |  New Delhi 

Drugs, Pharma, medicine

on Monday said the US health regulator has made six observations after the completion of inspection of active pharmaceutical ingredient (API) facility in Mekaguda Village, near Hyderabad.

The United States Food and Drug Administration (USFDA) conducted inspection at Kothur facility between August 5-9, 2019.

"At the end of the inspection, the facility received six observations - mostly procedural in nature. The company believes that none of observations are related to data integrity and that all the observations can be addressed within a short period of time," said in a regulatory filing.

said it will provide due justifications and corrective action plan within the next 15 working days to address the observations.

The company added that key points of the observations in Form 483 are the supplier and service provider agreements to be made more robust. Some procedural improvements in gowning section were recommended.

"Employees engaged in the manufacturing and packaging areas require more effective training. Procedural improvements needed in process revalidation protocols and approval of alternate supplier sources," the company added.

Natco Pharma said visual stains were observed in some early stage reactors that need further diagnosis and improvement. Status tags' for certain drying process equipment were not to be found.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, August 12 2019. 10:35 IST